Treatment of critically ill patients with candidemia.

Infectious Diseases Department, Hospital Clínico, Barcelona, Spain.
International Journal of Antimicrobial Agents (Impact Factor: 4.42). 11/2008; 32 Suppl 2:S93-7. DOI: 10.1016/S0924-8579(08)70007-4
Source: PubMed

ABSTRACT Early initiation of effective antimicrobial therapy is crucial for the prognosis of any infection, especially in the critically ill patient. This is particularly true in the case of candidemia. However, the earlier an empirical antimicrobial regimen is started, the greater the probability of diagnostic error and the possibility of side-effects. Recent experience of the clinical efficacy and good tolerance of echinocandins in the treatment of candidemia obliges us to review the indications for empirical antifungal treatment and the choice of antifungal agent in the critically ill patient.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Fungal infections are common in critically ill patients and are associated with increased morbidity and mortality. Candida spp are the most commonly isolated fungal pathogens. The last 2 decades have seen an increased incidence of fungal infections in critical illness and the emergence of new pathogenic fungal species and also the development of more effective (better bioavailability) and safer (less toxicity, fewer drug interactions) drugs. The distinction between colonization and infection can be difficult, and problems diagnosing infection may delay initiation of antifungal treatment. A number of factors have been identified that can help to distinguish patients at high risk for fungal infection. The antifungal agents that are most frequently used in the intensive care unit are the first- and second-generation azoles and the echinocandins; amphotericin B derivatives (mainly the liposomal agents) are less widely used because of adverse effects. The choice of antifungal agent in critically ill patients will depend on the aim of therapy (prophylaxis, pre-emptive, empiric, definitive), as well as on local epidemiology and specific properties of the drug (antifungal spectrum, efficacy, toxicity, pharmacokinetic/pharmacodynamic properties, cost). In this article we will review all these aspects and propose an algorithm to guide selection of antifungal agents in critically ill patients.
    Journal of critical care 10/2013; 28(5):717-27. · 2.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To study the epidemiology of candidemia and to identify risk factors for mortality among adult patients Retrospective analysis of patients with candidemia in a 2400-bed tertiary-care university hospital in Bangkok, Thailand from June 2006 to May 2009. During the study period, 147 patients (50% male) with clinically significant candidemia were identified, with a mean age of 61 years. The underlying conditions included renal failure (47%), abdominal surgery within 30 days (31%), diabetes (27%), hematologic malignancies (25%), solid malignancies (25%), neutropenia (23%), and liver disease (11%). Nearly all patients (98%) received antibacterial therapy within 30 days. The four most common Candida species were C. albicans (39%), C. tropicalis (28%), C. glabrata (22%) and C. parapsilosis (6%). Only sixty-nine patients (47%) received appropriate antifungal therapy within 72 hours. The 28-day all-cause mortality was 59%. By multivariate analysis, the independent risk factors associated with mortality were neutropenia from chemotherapy OR = 9.12 (2.94-28.31), septic shock OR = 3.66 (1.54-8.66), ICU admission OR = 3.18 (1.27-7.92), inappropriate antifungal therapy within 72 hours OR = 2.38 (1.07-5.28) and renal failure OR = 2.34 (1.07-5.13). Adult patients with candidemia had a high mortality rate particularly those receiving an inappropriate antifungal therapy. Empirical antifungal therapy should be considered in selected patients on the basis of underlying conditions, severity of illness and risk factors for mortality.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet 02/2013; 96 Suppl 2:S91-7.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Candida albicans infections have become increasingly recognised as being biofilm related. Recent studies have shown that there is a relationship between biofilm formation and poor clinical outcomes in patients infected with biofilm proficient strains. Here we have investigated a panel of clinical isolates in an attempt to evaluate their phenotypic and transcriptional properties in an attempt to differentiate and define levels of biofilm formation.
    BMC Microbiology 07/2014; 14(1):182. · 2.98 Impact Factor